Supply of SIR-Spheres® Y-90 Resin Microspheres (Radiopharmaceuticals)

This contract pertains to the supply of FDA-approved SIR-Spheres® Y-90 resin microspheres, which are radiopharmaceuticals used in selective internal radiation therapy (SIRT) for treating unresectable metastatic liver tumors originating from colorectal cancer. The contract involves providing these specialized microspheres, designed to deliver targeted radiation treatment directly to liver tumors, thereby offering a therapeutic option for patients who are not candidates for surgical tumor removal. Issued by the Department of Defense through the W40M Mrco East agency, the contract is a subcontract opportunity with a solicitation posted on May 15, 2026, and a response deadline of May 27, 2026. The place of performance is designated as Fort Bragg, with the relevant NAICS code being 325412, indicating a focus on pharmaceutical manufacturing. This opportunity underscores the military’s interest in advanced cancer therapies, particularly for its population and patient support facilities.